Ex Vivo Female Reproductive Tract Integration In a 3D Microphysiologic System

3D 微生理系统中的离体女性生殖道整合

基本信息

  • 批准号:
    8546384
  • 负责人:
  • 金额:
    $ 64.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-17 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The female reproductive tract is responsible for producing endocrine hormones, developing mature, healthy gametes (oocytes) and providing the site for fertilization and an environment that supports fetal development. There are five main organs in the female reproductive tract-the ovary, fallopian tubes, uterus, cervix and vagina. Each organ is responsible for unique aspects of reproductive function, but act integrally to support overall endocrine health, fertility, and fetal development. The reproductive tract organs are assembled from multiple cell lineages to create individual follicles (that enclose and support oocytes), oviductal/fallopian tubes, uterine myometrium and endometrium, the cervix and the vagina. Traditionally, research of the female reproductive tract has relied on two-dimensional (2D) cultures of isolated primary cells or immortalized cell lines grown on plastic and independent of adjacent cells, tissue architecture, and functional context. Moving to a three-dimensional (3D) culture environment has allowed us to better understand the function and interaction of cells within individual organs and interrogate interactions between tract tissues in co-cultures (e.g., the follicle and the ovarian surface cells, or the uterine myometrium and endometrium) to measure responses to normal reproductive hormones, pathologic conditions (such as high levels of androgens) or exposure to endocrine disruptors. New biomaterials and 3D culture systems have now presented us with the exciting opportunity to create a complete in vitro reproductive tract whereby each of the cultured organs can be assembled into a linked perfusion culture system. Just as the biological function and responses of 2D monolayer cell cultures differ from those of 3D-cultured organoids, we predict that the biology of the reproductive organs when studied in an integrated series will more closely recapitulate the in vivo environment. In Aims 1 and 2, we propose to develop in vitro cultures of human reproductive tissues that phenocopy in vivo function in terms of hormone production and response to the physiologically relevant reproductive hormones follicle-stimulating hormone (FSH) and estrogen. We will use the 3DKUBE" culture platform (KIYATEC), which not only permits control of perfusion to mimic tissue circulation, automated sampling for pharmacokinetic analyses, tissue imaging and in situ bioassays, but also will facilitate integration of the individal organ cultures into a functional in vitro female reproductive tract culture system in Aim 3. The successful development of an ex vivo female reproductive tract will give us the unique ability to interrogate normal hormonal responses of each organ in the context of the complete reproductive tract, as well as examine responses of the organs and system to agents that pose reproductive hazards. Toxicologic testing on female reproductive function and fertility is currently limited to animal studies. Our proposed Ex Vivo Female Reproductive Tract Integration In a 3D Microphysiologic System would permit earlier assessment of the effects of drugs, toxicants or vaccines on the human female reproductive system prior to exposure in clinical trials.
描述(由申请方提供):女性生殖道负责产生内分泌激素,发育成熟、健康的配子(卵母细胞),并提供受精位点和支持胎儿发育的环境。女性生殖道有五个主要器官:卵巢、输卵管、子宫、子宫颈和阴道。每个器官负责生殖功能的独特方面,但整体上支持整体内分泌健康,生育力和胎儿发育。生殖道器官由多个细胞谱系组装而成,以产生单个卵泡(包裹和支持卵母细胞)、输卵管/输卵管、子宫肌层和子宫内膜、宫颈和阴道。传统上,女性生殖道的研究依赖于分离的原代细胞或永生化细胞系的二维(2D)培养,这些细胞生长在塑料上,独立于相邻细胞、组织结构和功能背景。转移到三维(3D)培养环境使我们能够更好地了解单个器官内细胞的功能和相互作用,并询问器官中管道组织之间的相互作用。 共培养物(例如,卵泡和卵巢表面细胞,或子宫肌层和子宫内膜),以测量对正常生殖激素、病理条件(如高水平雄激素)或暴露于内分泌干扰物的反应。新的生物材料和3D培养系统现在为我们提供了一个令人兴奋的机会,可以创建一个完整的体外生殖道,从而将每个培养的器官组装成一个连接的灌注培养系统。正如2D单层细胞培养物的生物学功能和反应与3D培养的类器官不同一样,我们预测,在综合系列研究中,生殖器官的生物学将更接近体内环境。在目标1和2中,我们建议开发人类生殖组织的体外培养物,其在激素产生和对生理相关生殖激素促卵泡激素(FSH)和雌激素的反应方面在体内起表型作用。我们将使用3DKUBE”培养平台(KIYATEC),该平台不仅允许控制灌注以模拟组织循环、自动采样以进行药代动力学分析、组织成像和原位生物测定,而且还将有助于将单个器官培养物整合到目标3中的功能性体外女性生殖道培养系统中。离体雌性生殖道的成功开发将使我们能够在完整的生殖道背景下询问每个器官的正常激素反应,以及检查器官和系统对造成生殖危害的药剂的反应。关于雌性生殖功能和生育力的毒理学试验目前仅限于动物研究。我们提出的离体女性生殖道整合在3D微生理系统将允许早期评估药物,毒物或疫苗对人类女性生殖系统的影响之前,在临床试验中暴露。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Teresa K Woodruff其他文献

Making eggs: is it now or later?
做鸡蛋:是现在还是以后?
  • DOI:
    10.1038/nm1108-1190
  • 发表时间:
    2008-11-01
  • 期刊:
  • 影响因子:
    50.000
  • 作者:
    Teresa K Woodruff
  • 通讯作者:
    Teresa K Woodruff
Recreating the female reproductive tract in vitro using iPSC technology in a linked microfluidics environment
  • DOI:
    10.1186/scrt374
  • 发表时间:
    2013-12-01
  • 期刊:
  • 影响因子:
    7.300
  • 作者:
    Monica M Laronda;Joanna E Burdette;J Julie Kim;Teresa K Woodruff
  • 通讯作者:
    Teresa K Woodruff
MALE RESULTS OF THE SPARE STUDY: SURVEY FOR PRESERVATION OF ADOLESCENT REPRODUCTION
  • DOI:
    10.1016/s0022-5347(08)61917-5
  • 发表时间:
    2008-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Tobias S Kohler;Sarah Chan;Amul M Shah;Laxmi A Kondapalli;Marybeth Gerrity;Teresa K Woodruff;Robert Brannigan
  • 通讯作者:
    Robert Brannigan

Teresa K Woodruff的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Teresa K Woodruff', 18)}}的其他基金

Center for Reproductive Health After Disease
病后生殖健康中心
  • 批准号:
    9257196
  • 财政年份:
    2013
  • 资助金额:
    $ 64.2万
  • 项目类别:
Center for Reproductive Health After Disease
病后生殖健康中心
  • 批准号:
    8498720
  • 财政年份:
    2013
  • 资助金额:
    $ 64.2万
  • 项目类别:
Center for Reproductive Health After Disease
病后生殖健康中心
  • 批准号:
    8642665
  • 财政年份:
    2013
  • 资助金额:
    $ 64.2万
  • 项目类别:
Center for Reproductive Health After Disease
病后生殖健康中心
  • 批准号:
    8829686
  • 财政年份:
    2013
  • 资助金额:
    $ 64.2万
  • 项目类别:
Ex Vivo Female Reproductive Tract Integration In a 3D Microphysiologic System
3D 微生理系统中的离体女性生殖道整合
  • 批准号:
    8415387
  • 财政年份:
    2012
  • 资助金额:
    $ 64.2万
  • 项目类别:
Ex Vivo Female Reproductive Tract Integration In a 3D Microphysiologic System
3D 微生理系统中的离体女性生殖道整合
  • 批准号:
    8768923
  • 财政年份:
    2012
  • 资助金额:
    $ 64.2万
  • 项目类别:
Ex Vivo Female Reproductive Tract Integration In a 3D Microphysiologic System
3D 微生理系统中的离体女性生殖道整合
  • 批准号:
    8730764
  • 财政年份:
    2012
  • 资助金额:
    $ 64.2万
  • 项目类别:
Ex Vivo Female Reproductive Tract Integration In a 3D Microphysiologic System
3D 微生理系统中的离体女性生殖道整合
  • 批准号:
    8929340
  • 财政年份:
    2012
  • 资助金额:
    $ 64.2万
  • 项目类别:
Ex Vivo Female Reproductive Tract Integration In a 3D Microphysiologic System
3D 微生理系统中的离体女性生殖道整合
  • 批准号:
    9013074
  • 财政年份:
    2012
  • 资助金额:
    $ 64.2万
  • 项目类别:
Ex Vivo Female Reproductive Tract Integration In a 3D Microphysiologic System
3D 微生理系统中的离体女性生殖道整合
  • 批准号:
    9105454
  • 财政年份:
    2012
  • 资助金额:
    $ 64.2万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 64.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 64.2万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 64.2万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 64.2万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 64.2万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 64.2万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 64.2万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 64.2万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 64.2万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 64.2万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了